Main Article Content

Shobhana Jorvekar
Mallikarjun Salagar
Akshay Bhandari


Purpose: Primary open angle glaucoma (POAG) is one such field in Ophthalmology where ophthalmologists have failed to stop blindness due to it. All the available treatment modalities are directed towards the reduction of intraocular pressure (IOP) but without interfering the basic aetiopathogenesis. In this study we propose to study efficacy, potency and adverse effects of topical Timolol and Betaxalol in primary open angle glaucoma.  Methodology: A comparative study of topical Betaxalol 0.5% and Timolol 0.5% in the management of POAG was conducted at Tertiary care hospital. Fifty patients of newly diagnosed POAG of different age, sex, religion from both urban and rural population attending eye OPD were included in this study. 25 patients were treated with topical Timolol maleate 0.5% ophthalmic solution BD and 25 patients were treated with topical 0.5% Betaxalol hydrochloride phthalmic solution BD. At 20 weeks follow up IOP levels n both the groups measured by applanation tonometer were compare to each other.  Results: In this study a total of 50 patients with POAG were studied. 25 patients were treated with Timolol maleate 0.5% ophthalmic solution and 25 patients were treated with 0.5% Betaxalol hydrochloride ophthalmic solution. Out of 50 patients, 29 (58%) were male and 21(42%) were female patients. POAG was most common in the age group of 51-60 years with average age 51.50 (S.D. 9.8) years. Average age in males was 54.50 years, while in female it was 49.31 years. Conclusion: both Timolol and Betaxalol are effective in decreasing IOP in POAG patients. The magnitude of Timolol in decreasing IOP is more as compared to Betaxalol. The selective beta 1 adrenergic inhibition of Betaxalol provides an added benefit for those patients in whom beta 2 blockade could be harmful.

Article Details

How to Cite
Jorvekar, S., Salagar, M., & Bhandari, A. (2018). A COMPARATIVE STUDY OF TOPICAL BETAXALOL AND TIMOLOL FOR THEIR EFFICACY AND SIDE EFFECTS. International Journal of Clinical and Biomedical Research, 4(3), 6-9. https://doi.org/10.31878/ijcbr.2018.43.02


1. Adler F: Physiology of the eye, 9th edition, 1992.
2. Allen Robert. C, Hertzmark E llen, Alexandes. M et al; A double masked comparison of Betaxalol and Timolol in the treatment of open angle glaucoma. Am J Oohthalmol.101: 535-541; May 1986.
3. Messemer C, Flammer Stumpung D: Influence of Betaxalol and Timolol on the visual fields of patients with glaucoma. Am J Ophthalmol.112:678-681, Dec 1991.
4. Zimerman Thom J, Kass Micheal A: Timolol Maleate- efficacy and safety. Arch Ophthalmol. Vol 97: 656-658, Apr 1979.
5. Berry David P, Buskirk Van E. M, Shields Bruce M: Betaxalol and Timolol. A comparison of efficacy and side effects. Arch Ophthalmol. Vol.102: 42-45, Jan 1984.
6. Stewart – Robert H, Kimbrogh Richard L. Ward, Richard L: Betaxalol Vs Timolol- a six month double blind comparison. Arch Ophthalmol. Vol 104: 46-48, Jan 1986.
7. Hutzelmann J, Owens S, Shedden A, Adamsons I,Vargas Eand the International clinical equivalence study group. Comparison of the safety and efficacy of fixed combination of Dorzolamide/Timolol and the concomimitant administration of Dorzolamide and Timolol: A clinical equivalence study. Br J Ophthalmol 1998; 82: 1249-53.
8. Shields MB. The intraocular pressure. In. Text Book of Glaucoma 2nd edition. Mosby-Year Book, 1987. pp 60.
9. West RD, Lischwe DT, Thompson MV, Ide HC. Comparative efficacy of the beta- blockers for the prevention of increased IOP after cataract extraction.
Am J Ophthalmol 1988; 106: 168-73.
10. Feghali GJ, Kaufman LP. Decreased IOP in the hypertensive human eye with betaxolol, a beta-1 aderanergic antagonist. Am J Ophthalmol 1985; 100: 777-82.